EANM 2024: Join Us for Cutting-Edge Insights at the OncoBeta Symposium
OncoBeta is thrilled to announce our participation in the upcoming EANM 2024 Congress in Hamburg! As a leader in innovative non-invasive treatments for non-melanoma skin cancer, we are eager to engage with the global nuclear medicine community, share our latest advancements, and connect with professionals driving the future of theranostics and radiopharmaceuticals.
The European Association of Nuclear Medicine (EANM) Congress is one of the most prestigious events in the field, bringing together top researchers, clinicians, and industry experts. For us at OncoBeta, it represents a unique opportunity to highlight our groundbreaking work in the field of epidermal radioisotope therapy for non-melanoma skin cancers, and our mission to improve patients’ quality of life.
Our Highlight: The OncoBeta-Sponsored Symposium
This year, we are proud to sponsor a special symposium at the congress, featuring the latest research results from two major projects: Bologna University’s findings and the much-anticipated EPIC-Skin 12-month interim results. These studies have advanced the understanding of rhenium-based therapies and shown remarkable progress in treating non-melanoma skin cancer.
Where: EANM Congress, Hall Y1-Y3
When: 13:00 – 14:30 on Sunday 20th October 2024
Speakers:
- Prof. Paolo Castellucci (Nuclear Medicine Physician, Italy)
- Prof. Siroos Mirzaei (Head of Nuclear Medicine, Austria)
- A/Prof. Joe Cardaci (Nuclear Medicine Physician, Australia)
Bologna University: Groundbreaking Advances in Rhenium Therapy
Led by a team of researchers at the renowned Bologna University, OncoBeta has been involved in cutting-edge research that further explores the therapeutic potential of rhenium-188 for non-melanoma skin cancer. The symposium will reveal the latest clinical data from Bologna, showcasing the effectiveness of Rhenium-SCT® as a non-invasive, skin-sparing treatment option. Attendees will learn about:
- The progress in targeting and treating skin cancer using rhenium isotopes.
- The significant patient outcomes achieved in terms of healing, recovery, and overall patient satisfaction.
- The potential of this therapy to revolutionise the treatment landscape for non-melanoma skin cancer.
EPIC-Skin: Pioneering Research Redefining the Future of Skin Cancer Treatment
The EPIC-Skin clinical study has been one of the most eagerly awaited trials in the field, and we’re excited to present the 12-month interim results during the symposium. This study examines efficacy, safety, quality of life and the cosmetic outcomes of Rhenium-SCT® on a large cohort of non-melanoma skin cancer patients. The symposium will delve into:
- Data highlighting the sustained success rates of rhenium-based therapy.
- Real-world applications and how this research is pushing the boundaries of current treatment standards.
- Insight into robust data from patient reported outcomes including comfort of treatment, social considerations, and cosmetic outcome.
Presentations will provide attendees with valuable insights into the latest innovations in rhenium therapy and its potential to change the standard of care for patients globally.
Networking and Expert Engagement
Beyond the symposium, the EANM congress provides a perfect forum for meaningful discussions with OncoBeta’s expert team. We invite congress attendees to visit our booth for more information on our Rhenium-SCT® technology, clinical trial developments, and our vision for expanding access to non-invasive skin cancer treatments around the world.
Why Attend OncoBeta’s Sponsored Symposium?
- Exclusive Research Insights: Be among the first to learn about the most recent clinical findings from two significant studies.
- Interactive Q&A: Engage directly with the leading researchers from Bologna University and EPIC-Skin in an interactive Q&A session.
Join Us at EANM 2024!
The EANM congress is a prime opportunity for nuclear medicine professionals to stay ahead of the latest research, treatments, and innovations. OncoBeta’s Sponsored Symposium is set to be a highlight of the event, offering groundbreaking information that could change the future of non-melanoma skin cancer therapy.
We look forward to seeing you in Hamburg and sharing the exciting results from our pioneering research. Together, we can continue to push the boundaries of medical science and bring innovative, patient-centric solutions to those who need them most.
Mark your calendars for the symposium, and don’t forget to visit the OncoBeta booth for more in-depth conversations!
